Matches in SemOpenAlex for { <https://semopenalex.org/work/W2412739800> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2412739800 endingPage "1002" @default.
- W2412739800 startingPage "997" @default.
- W2412739800 abstract "One hundred and ten patients with acute proximal deep-vein thrombosis were randomized in a sequential dose-finding design, to receive continuous intravenous infusion of napsagatran, a novel synthetic thrombin-inhibitor, at a fixed dose of 5 mg/h (n = 37) or 9 mg/h (n = 26), or APTT-adjusted unfractionated heparin (n = 47). Oral anticoagulants were started on the 2nd day and the study drug was discontinued from the 5th treatment day, as soon as the International Normalized Ratio was above 2. Control venogram (97 venogram pairs evaluable) after 5-8 days of treatment showed improvement in 3 napsagatran-treated patients (versus none in heparin-treated patients) and worsening in 4 napsagatran-treated patients (versus 2 in heparin-treated patients). The venographic Marder's score did not change among the treatment groups. New lung scan perfusion defects (99 scintigram pairs evaluable) occurred in 4 (11%), 4 (21%), and 4 (10%) patients in the napsagatran (5 mg/h) group, in the napsagatran (9 mg/h) group, and in the heparin control group, respectively. There was no statistically significant difference in any of these endpoints between the 3 groups. No major bleeding was observed and the rare minor bleedings occurred at a similar rate in the three treatment groups. In conclusion, the ADVENT trial has shown data that suggest comparable efficacy and safety of a synthetic, direct thrombin inhibitor (napsagatran) and conventional heparin therapy for treatment of proximal DVT. These results suggest that synthetic direct thrombin inhibitors are a promising class of antithrombotic agents which deserves further development in this field." @default.
- W2412739800 created "2016-06-24" @default.
- W2412739800 creator A5001095455 @default.
- W2412739800 creator A5006834246 @default.
- W2412739800 creator A5022304478 @default.
- W2412739800 creator A5067642836 @default.
- W2412739800 creator A5071341802 @default.
- W2412739800 creator A5072237302 @default.
- W2412739800 date "1997-09-01" @default.
- W2412739800 modified "2023-09-23" @default.
- W2412739800 title "An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial." @default.
- W2412739800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9308743" @default.
- W2412739800 hasPublicationYear "1997" @default.
- W2412739800 type Work @default.
- W2412739800 sameAs 2412739800 @default.
- W2412739800 citedByCount "7" @default.
- W2412739800 crossrefType "journal-article" @default.
- W2412739800 hasAuthorship W2412739800A5001095455 @default.
- W2412739800 hasAuthorship W2412739800A5006834246 @default.
- W2412739800 hasAuthorship W2412739800A5022304478 @default.
- W2412739800 hasAuthorship W2412739800A5067642836 @default.
- W2412739800 hasAuthorship W2412739800A5071341802 @default.
- W2412739800 hasAuthorship W2412739800A5072237302 @default.
- W2412739800 hasConcept C126322002 @default.
- W2412739800 hasConcept C141071460 @default.
- W2412739800 hasConcept C162156334 @default.
- W2412739800 hasConcept C2776301958 @default.
- W2412739800 hasConcept C2776710957 @default.
- W2412739800 hasConcept C2777015399 @default.
- W2412739800 hasConcept C2777292125 @default.
- W2412739800 hasConcept C2777557582 @default.
- W2412739800 hasConcept C2778205648 @default.
- W2412739800 hasConcept C2778810321 @default.
- W2412739800 hasConcept C2778959117 @default.
- W2412739800 hasConcept C2779161974 @default.
- W2412739800 hasConcept C2780011451 @default.
- W2412739800 hasConcept C2780868729 @default.
- W2412739800 hasConcept C42219234 @default.
- W2412739800 hasConcept C57002609 @default.
- W2412739800 hasConcept C71924100 @default.
- W2412739800 hasConcept C89560881 @default.
- W2412739800 hasConceptScore W2412739800C126322002 @default.
- W2412739800 hasConceptScore W2412739800C141071460 @default.
- W2412739800 hasConceptScore W2412739800C162156334 @default.
- W2412739800 hasConceptScore W2412739800C2776301958 @default.
- W2412739800 hasConceptScore W2412739800C2776710957 @default.
- W2412739800 hasConceptScore W2412739800C2777015399 @default.
- W2412739800 hasConceptScore W2412739800C2777292125 @default.
- W2412739800 hasConceptScore W2412739800C2777557582 @default.
- W2412739800 hasConceptScore W2412739800C2778205648 @default.
- W2412739800 hasConceptScore W2412739800C2778810321 @default.
- W2412739800 hasConceptScore W2412739800C2778959117 @default.
- W2412739800 hasConceptScore W2412739800C2779161974 @default.
- W2412739800 hasConceptScore W2412739800C2780011451 @default.
- W2412739800 hasConceptScore W2412739800C2780868729 @default.
- W2412739800 hasConceptScore W2412739800C42219234 @default.
- W2412739800 hasConceptScore W2412739800C57002609 @default.
- W2412739800 hasConceptScore W2412739800C71924100 @default.
- W2412739800 hasConceptScore W2412739800C89560881 @default.
- W2412739800 hasIssue "3" @default.
- W2412739800 hasLocation W24127398001 @default.
- W2412739800 hasOpenAccess W2412739800 @default.
- W2412739800 hasPrimaryLocation W24127398001 @default.
- W2412739800 hasRelatedWork W1969361305 @default.
- W2412739800 hasRelatedWork W1988066241 @default.
- W2412739800 hasRelatedWork W2069944229 @default.
- W2412739800 hasRelatedWork W2083172002 @default.
- W2412739800 hasRelatedWork W2096373077 @default.
- W2412739800 hasRelatedWork W2408297979 @default.
- W2412739800 hasRelatedWork W2410486011 @default.
- W2412739800 hasRelatedWork W2412739800 @default.
- W2412739800 hasRelatedWork W2416730230 @default.
- W2412739800 hasRelatedWork W2418903359 @default.
- W2412739800 hasVolume "78" @default.
- W2412739800 isParatext "false" @default.
- W2412739800 isRetracted "false" @default.
- W2412739800 magId "2412739800" @default.
- W2412739800 workType "article" @default.